Saturday, 31 October 2026European Markets

HYBRID SOFTWARE GR Stock Was Up By 9.09% On Monday

Loading stream...

(VIANEWS) - The Market ended the session with HYBRID SOFTWARE GR (HYSG.BR) rising 9.09% to €3.16 on Monday, after five sequential sessions in a row of losses. BEL 20 dropped 0.6% to €3,685.19, after three consecutive sessions in a row of gains, on what was a somewhat down trend trading session today.

HYBRID SOFTWARE GR's last close was €2.90, 41.53% under its 52-week high of €4.96.

About HYBRID SOFTWARE GR

Hybrid Software Group PLC, together with its subsidiaries, develops software and hardware technology solutions for graphics and industrial inkjet printing in the United Kingdom, rest of Europe, North and South America, and Asia. The company offers Harlequin Core, a raster image processor (RIP) software that converts text and image data from various file formats, including PDF, TIFF, and JPEG files; ScreenPro, a software that converts tone image data into ready-to-print halftone in real-time; and Mako SDK, a software that creates, rasterizes, converts, analyses, and optimizes various page description languages, as well as allows print software developers to control over colour, fonts, text, images, vector content, and metadata. It also provides Harlequin Direct, a software that drives print data directly to the printer electronics instead of buffering them on mass storage devices; SmartDFE, a turnkey digital front end based on Harlequin Direct, CLOUDFLOW, and Meteor for digital printing of labels and packaging; Navigator Harlequin RIP and Workflow, a software that offers prepress environments to interpretation of PostScript, PDF, and EPS format files; Navigator DFE, a software that helps to prepare jobs, manage colour, and control digital output devices built with Memjet or any standard inkjet printhead; and Output Device Interfaces, a hardware and software solutions to connect RIPs to computer-to-plate devices, imagesetters, proofers, digital presses, high-speed copiers, and inkjet printers. The company was formerly known as Global Graphics PLC and changed its name to Hybrid Software Group PLC in October 2021. Hybrid Software Group PLC was founded in 1986 and is headquartered in Cambridge, the United Kingdom.

Earnings Per Share

As for profitability, HYBRID SOFTWARE GR has a trailing twelve months EPS of €0.02.

PE Ratio

HYBRID SOFTWARE GR has a trailing twelve months price to earnings ratio of 158. Meaning, the purchaser of the share is investing €158 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.54%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HYBRID SOFTWARE GR's stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

HYBRID SOFTWARE GR's stock is valued at €3.16 at 21:30 EST, way under its 52-week high of €4.96 and way higher than its 52-week low of €2.56.

Moving Average

HYBRID SOFTWARE GR's value is under its 50-day moving average of €3.31 and way under its 200-day moving average of €3.63.

Volatility

HYBRID SOFTWARE GR's last week, last month's, and last quarter's current intraday variation average was a negative 3.35%, a negative 1.03%, and a positive 2.26%.

HYBRID SOFTWARE GR's highest amplitude of average volatility was 3.35% (last week), 2.29% (last month), and 2.26% (last quarter).

More news about HYBRID SOFTWARE GR (HYSG.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com